Details of the Drug

General Information of Drug (ID: DM1XBHS)

Drug Name
Pentazocine
Synonyms
Fortalgesic; Fortalin; Fortral; Lexir; Liticon; Pentagin; Pentazocaine; Pentazocin; Pentazocina; Pentazocinum; Sosegon; Soseton; Sosigon; Talacen; Talwan; Pentazocina [DCIT]; NIH 7958; WIN 20228; Algopent (free base); Fortal (TN); Fortral (TN); Fortwin (TN); KF-1820; L-pentazocine; Pentazocinum [INN-Latin]; Talacen (TN); Talwin (TN); Talwin NX (TN); Talwin PX (TN); II-C-2; Pentazocine (JP15/USP/INN); Pentazocine [USAN:INN:BAN:JAN]; Pentazocine, Pentazocin, Sosegon, WIN 20228; (2R*,6R*,11R*)-1,2,3,4,5,6-Hexahydro-6,11-dimethyl-3-(3-methyl-2-butenyl)-2,6-methano-3-benzazocin-8-ol; (2R,6R,11R)-6,11-dimethyl-3-(3-methylbut-2-en-1-yl)-1,2,3,4,5,6-hexahydro-2,6-methano-3-benzazocin-8-ol; (2alpha,6alpha,11R*)-(1)-1,2,3,4,5,6-Hexahydro-6,11-dimethyl-3-(3-methylbut-2-enyl)-2,6-methano-3-benzazocin-8-ol; 1,2,3,4,5,6-Hexahydro-6,11-dimethyl-3-(3-methyl-2-butenyl)-2,6-methano-3-benzazocin-8-ol; 1,2,3,4,5,6-Hexahydro-6,11-dimethyl-3-(3-methylbut-2-enyl)-2,6-methano-3-benzazocin-8-ol; 2'-Hydroxy-5,9-dimethyl-2-(3,3-dimethylallyl)-6,7-benzomorphan; 2-(3,3-Dimethylallyl)-2',2'-hydroxy-5,9-dimethyl-6,7-benzomorphan; 2-(3,3-Dimethylallyl)cyclazocine; 2-Dimethylallyl-5,9-dimethyl-2'-hydroxybenzomorphan; 3-(3-Methyl-2-butenyl)-1,2,3,4,5,6-hexahydro-6,11-dimethyl-2,6-methano-3-benzazocin-8-ol
Indication
Disease Entry ICD 11 Status REF
Pain MG30-MG3Z Approved [1]
Therapeutic Class
Anesthetics
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 0 Molecular Weight (mw) 285.4
Topological Polar Surface Area (xlogp) 3.3
Rotatable Bond Count (rotbonds) 2
Hydrogen Bond Donor Count (hbonddonor) 1
Hydrogen Bond Acceptor Count (hbondacc) 2
ADMET Property
Absorption
The drug is well absorbed from the gastrointestinal tract [2]
BDDCS Class
Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 2: low solubility and high permeability [3]
Clearance
The drug present in the plasma can be removed from the body at the rate of 23 mL/min/kg [4]
Elimination
15% of drug is excreted from urine in the unchanged form [3]
Half-life
The concentration or amount of drug in body reduced by one-half in 2 - 3 hours [4]
Metabolism
The drug is metabolized via the hepatic [2]
MRTD
The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 1.75172 micromolar/kg/day [5]
Unbound Fraction
The unbound fraction of drug in plasma is 0.39% [4]
Vd
Fluid volume that would be required to contain the amount of drug present in the body at the same concentration as in the plasma 3.4 L/kg [4]
Water Solubility
The ability of drug to dissolve in water is measured as 0.0449 mg/mL [3]
Chemical Identifiers
Formula
C19H27NO
IUPAC Name
(1R,9R,13R)-1,13-dimethyl-10-(3-methylbut-2-enyl)-10-azatricyclo[7.3.1.02,7]trideca-2(7),3,5-trien-4-ol
Canonical SMILES
C[C@H]1[C@H]2CC3=C([C@@]1(CCN2CC=C(C)C)C)C=C(C=C3)O
InChI
InChI=1S/C19H27NO/c1-13(2)7-9-20-10-8-19(4)14(3)18(20)11-15-5-6-16(21)12-17(15)19/h5-7,12,14,18,21H,8-11H2,1-4H3/t14-,18+,19+/m0/s1
InChIKey
VOKSWYLNZZRQPF-GDIGMMSISA-N
Cross-matching ID
PubChem CID
441278
ChEBI ID
CHEBI:7982
CAS Number
359-83-1
DrugBank ID
DB00652
TTD ID
D0W6DG
VARIDT ID
DR01286

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Opioid receptor (OPR) TTN4QDT NOUNIPROTAC Antagonist [6], [7]

Drug Transporter (DTP)
DTP Name DTP ID UniProt ID MOA REF
P-glycoprotein 1 (ABCB1) DTUGYRD MDR1_HUMAN Substrate [8]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Pentazocine
DDI Drug Name DDI Drug ID Severity Mechanism Disease REF
Oxymorphone DM65AGJ Major Additive hypotensive effects by the combination of Pentazocine and Oxymorphone. Pain [MG30-MG3Z] [25]
Levorphanol DMGS80V Major Additive CNS depression effects by the combination of Pentazocine and Levorphanol. Pain [MG30-MG3Z] [25]
Dezocine DMJDB0Y Major Additive CNS depression effects by the combination of Pentazocine and Dezocine. Pain [MG30-MG3Z] [25]
Flavoxate DMKV4NL Moderate Additive antimotility effects by the combination of Pentazocine and Flavoxate. Pain [MG30-MG3Z] [26]
Buprenorphine DMPRI8G Major Additive CNS depression effects by the combination of Pentazocine and Buprenorphine. Pain [MG30-MG3Z] [25]
Hydrocodone DMQ2JO5 Major Additive hypotensive effects by the combination of Pentazocine and Hydrocodone. Pain [MG30-MG3Z] [25]
⏷ Show the Full List of 6 DDI Information of This Drug
Coadministration of a Drug Treating the Disease Different from Pentazocine (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Scopolamine DMOM8AL Moderate Additive CNS depression effects by the combination of Pentazocine and Scopolamine. Addictive disorder [6C50-6C5Z] [26]
Methylphenobarbital DMDSWAG Major Additive CNS depression effects by the combination of Pentazocine and Methylphenobarbital. Anxiety disorder [6B00-6B0Z] [27]
Halazepam DMPFWO6 Major Additive CNS depression effects by the combination of Pentazocine and Halazepam. Anxiety disorder [6B00-6B0Z] [28]
Chlormezanone DMTWUXR Major Additive CNS depression effects by the combination of Pentazocine and Chlormezanone. Anxiety disorder [6B00-6B0Z] [28]
Oxazepam DMXNZM4 Major Additive CNS depression effects by the combination of Pentazocine and Oxazepam. Anxiety disorder [6B00-6B0Z] [28]
Desipramine DMT2FDC Moderate Additive serotonergic effects by the combination of Pentazocine and Desipramine. Attention deficit hyperactivity disorder [6A05] [29]
Cariprazine DMJYDVK Major Additive CNS depression effects by the combination of Pentazocine and Cariprazine. Bipolar disorder [6A60] [28]
Loperamide DMOJZQ9 Moderate Additive CNS depression effects by the combination of Pentazocine and Loperamide. Bowel habit change [ME05] [30]
Dihydrocodeine DMB0FWL Major Additive hypotensive effects by the combination of Pentazocine and Dihydrocodeine. Chronic pain [MG30] [25]
Levomilnacipran DMV26S8 Major Additive serotonergic effects by the combination of Pentazocine and Levomilnacipran. Chronic pain [MG30] [31]
Olopatadine DMKMWQG Moderate Additive CNS depression effects by the combination of Pentazocine and Olopatadine. Conjunctiva disorder [9A60] [32]
Propofol DMB4OLE Moderate Additive CNS depression effects by the combination of Pentazocine and Propofol. Corneal disease [9A76-9A78] [33]
Ethanol DMDRQZU Moderate Additive CNS depression effects by the combination of Pentazocine and Ethanol. Cystitis [GC00] [34]
Sertraline DM0FB1J Major Additive serotonergic effects by the combination of Pentazocine and Sertraline. Depression [6A70-6A7Z] [31]
Trimipramine DM1SC8M Moderate Additive serotonergic effects by the combination of Pentazocine and Trimipramine. Depression [6A70-6A7Z] [29]
Vilazodone DM4LECQ Major Additive serotonergic effects by the combination of Pentazocine and Vilazodone. Depression [6A70-6A7Z] [31]
Nefazodone DM4ZS8M Major Additive serotonergic effects by the combination of Pentazocine and Nefazodone. Depression [6A70-6A7Z] [31]
Paroxetine DM5PVQE Major Additive serotonergic effects by the combination of Pentazocine and Paroxetine. Depression [6A70-6A7Z] [31]
Selegiline DM6034S Major Additive serotonergic effects by the combination of Pentazocine and Selegiline. Depression [6A70-6A7Z] [35]
Vortioxetine DM6F1PU Major Additive serotonergic effects by the combination of Pentazocine and Vortioxetine. Depression [6A70-6A7Z] [31]
Milnacipran DMBFE74 Major Additive serotonergic effects by the combination of Pentazocine and Milnacipran. Depression [6A70-6A7Z] [31]
Escitalopram DMFK9HG Major Additive serotonergic effects by the combination of Pentazocine and Escitalopram. Depression [6A70-6A7Z] [31]
Desvenlafaxine DMHD4PE Major Additive serotonergic effects by the combination of Pentazocine and Desvenlafaxine. Depression [6A70-6A7Z] [31]
OPC-34712 DMHG57U Major Additive CNS depression effects by the combination of Pentazocine and OPC-34712. Depression [6A70-6A7Z] [28]
Clomipramine DMINRKW Moderate Additive serotonergic effects by the combination of Pentazocine and Clomipramine. Depression [6A70-6A7Z] [29]
Trazodone DMK1GBJ Moderate Additive serotonergic effects by the combination of Pentazocine and Trazodone. Depression [6A70-6A7Z] [29]
Doxepin DMPI98T Moderate Additive serotonergic effects by the combination of Pentazocine and Doxepin. Depression [6A70-6A7Z] [29]
Maprotiline DMPWB7T Moderate Additive serotonergic effects by the combination of Pentazocine and Maprotiline. Depression [6A70-6A7Z] [29]
Esketamine DMVU687 Moderate Additive CNS depression effects by the combination of Pentazocine and Esketamine. Depression [6A70-6A7Z] [35]
Mepenzolate DM8YU2F Moderate Additive CNS depression effects by the combination of Pentazocine and Mepenzolate. Digestive system disease [DE2Z] [26]
Oxybutynine DMJPBAX Moderate Additive CNS depression effects by the combination of Pentazocine and Oxybutynine. Discovery agent [N.A.] [26]
Heroin diacetylmorphine DMDBWHY Major Additive CNS depression effects by the combination of Pentazocine and Heroin diacetylmorphine. Dissociative neurological symptom disorder [6B60] [27]
Diazepam DM08E9O Major Additive CNS depression effects by the combination of Pentazocine and Diazepam. Epilepsy/seizure [8A61-8A6Z] [28]
Primidone DM0WX6I Major Additive CNS depression effects by the combination of Pentazocine and Primidone. Epilepsy/seizure [8A61-8A6Z] [28]
Gabapentin DM6T924 Major Additive CNS depression effects by the combination of Pentazocine and Gabapentin. Epilepsy/seizure [8A61-8A6Z] [36]
Clonazepam DMTO13J Major Additive CNS depression effects by the combination of Pentazocine and Clonazepam. Epilepsy/seizure [8A61-8A6Z] [28]
Phenobarbital DMXZOCG Major Additive CNS depression effects by the combination of Pentazocine and Phenobarbital. Epilepsy/seizure [8A61-8A6Z] [28]
Dantrolene DM1D8XY Major Additive CNS depression effects by the combination of Pentazocine and Dantrolene. Fever [MG26] [28]
Solifenacin DMG592Q Moderate Additive CNS depression effects by the combination of Pentazocine and Solifenacin. Functional bladder disorder [GC50] [26]
Tolterodine DMSHPW8 Moderate Additive CNS depression effects by the combination of Pentazocine and Tolterodine. Functional bladder disorder [GC50] [26]
Propantheline DM2EN6G Moderate Additive CNS depression effects by the combination of Pentazocine and Propantheline. Gastric ulcer [DA60] [26]
Belladonna DM2RBWK Moderate Additive antimotility effects by the combination of Pentazocine and Belladonna. Infectious gastroenteritis/colitis [1A40] [26]
Suvorexant DM0E6S3 Major Additive CNS depression effects by the combination of Pentazocine and Suvorexant. Insomnia [7A00-7A0Z] [28]
Amobarbital DM0GQ8N Major Additive CNS depression effects by the combination of Pentazocine and Amobarbital. Insomnia [7A00-7A0Z] [28]
Ramelteon DM7IW9J Major Additive CNS depression effects by the combination of Pentazocine and Ramelteon. Insomnia [7A00-7A0Z] [28]
Flurazepam DMAL4G0 Major Additive CNS depression effects by the combination of Pentazocine and Flurazepam. Insomnia [7A00-7A0Z] [28]
Triazolam DMETYK5 Major Additive CNS depression effects by the combination of Pentazocine and Triazolam. Insomnia [7A00-7A0Z] [28]
Zaleplon DMGFWSM Major Additive CNS depression effects by the combination of Pentazocine and Zaleplon. Insomnia [7A00-7A0Z] [28]
Propiomazine DMKY8V1 Major Additive CNS depression effects by the combination of Pentazocine and Propiomazine. Insomnia [7A00-7A0Z] [28]
Tasimelteon DMLOQ1V Major Additive CNS depression effects by the combination of Pentazocine and Tasimelteon. Insomnia [7A00-7A0Z] [28]
Paraldehyde DMOC1BX Major Additive CNS depression effects by the combination of Pentazocine and Paraldehyde. Insomnia [7A00-7A0Z] [28]
ITI-007 DMUQ1DO Major Additive CNS depression effects by the combination of Pentazocine and ITI-007. Insomnia [7A00-7A0Z] [28]
Quazepam DMY4D87 Major Additive CNS depression effects by the combination of Pentazocine and Quazepam. Insomnia [7A00-7A0Z] [28]
Estazolam DMZGXUM Major Additive CNS depression effects by the combination of Pentazocine and Estazolam. Insomnia [7A00-7A0Z] [28]
Polyethylene glycol DM4I1JP Moderate Increased risk of lowers seizure threshold by the combination of Pentazocine and Polyethylene glycol. Irritable bowel syndrome [DD91] [37]
Clidinium DMUMQZ0 Moderate Additive antimotility effects by the combination of Pentazocine and Clidinium. Irritable bowel syndrome [DD91] [26]
Dicyclomine DMZSDGX Moderate Additive antimotility effects by the combination of Pentazocine and Dicyclomine. Irritable bowel syndrome [DD91] [26]
Remimazolam DMLVSYX Major Additive CNS depression effects by the combination of Pentazocine and Remimazolam. Labour/delivery anaesthesia complication [JB0C] [28]
Allopregnanolone DMNLHAC Moderate Additive CNS depression effects by the combination of Pentazocine and Allopregnanolone. Mental/behavioural/neurodevelopmental disorder [6E20-6E8Z] [38]
Flibanserin DM70DTN Moderate Additive CNS depression effects by the combination of Pentazocine and Flibanserin. Mood disorder [6A60-6E23] [39]
Thalidomide DM70BU5 Moderate Additive CNS depression effects by the combination of Pentazocine and Thalidomide. Multiple myeloma [2A83] [40]
Prasugrel DM7MT6E Moderate Altered absorption of Pentazocine due to GI dynamics variation caused by Prasugrel. Myocardial infarction [BA41-BA43] [41]
Metoclopramide DMFA5MY Moderate Antagonize the effect of Pentazocine when combined with Metoclopramide. Nausea/vomiting [MD90] [42]
Granisetron DMIUW25 Major Additive serotonergic effects by the combination of Pentazocine and Granisetron. Nausea/vomiting [MD90] [43]
Dolasetron DMMG26Z Major Additive serotonergic effects by the combination of Pentazocine and Dolasetron. Nausea/vomiting [MD90] [43]
Ondansetron DMOTQ1I Major Additive serotonergic effects by the combination of Pentazocine and Ondansetron. Nausea/vomiting [MD90] [43]
Bupropion DM5PCS7 Major Increased risk of lowers seizure threshold by the combination of Pentazocine and Bupropion. Nicotine use disorder [6C4A] [44]
Sibutramine DMFJTDI Major Additive serotonergic effects by the combination of Pentazocine and Sibutramine. Obesity [5B80-5B81] [45]
Lorcaserin DMG6OYJ Major Additive serotonergic effects by the combination of Pentazocine and Lorcaserin. Obesity [5B80-5B81] [46]
Dexfenfluramine DMJ7YDS Major Additive serotonergic effects by the combination of Pentazocine and Dexfenfluramine. Obesity [5B80-5B81] [31]
Levomethadyl Acetate DM06HG5 Major Additive CNS depression effects by the combination of Pentazocine and Levomethadyl Acetate. Opioid use disorder [6C43] [25]
Apraclonidine DMO4PVE Moderate Additive CNS depression effects by the combination of Pentazocine and Apraclonidine. Optic nerve disorder [9C40] [47]
Biperiden DME78OA Moderate Additive CNS depression effects by the combination of Pentazocine and Biperiden. Parkinsonism [8A00] [48]
Pimavanserin DMR7IVC Major Additive CNS depression effects by the combination of Pentazocine and Pimavanserin. Parkinsonism [8A00] [28]
Orphenadrine DMW542E Major Additive CNS depression effects by the combination of Pentazocine and Orphenadrine. Parkinsonism [8A00] [28]
Methylscopolamine DM5VWOB Moderate Additive CNS depression effects by the combination of Pentazocine and Methylscopolamine. Peptic ulcer [DA61] [26]
Quetiapine DM1N62C Major Additive CNS depression effects by the combination of Pentazocine and Quetiapine. Schizophrenia [6A20] [49]
Mesoridazine DM2ZGAN Major Additive CNS depression effects by the combination of Pentazocine and Mesoridazine. Schizophrenia [6A20] [49]
Thioridazine DM35M8J Major Additive CNS depression effects by the combination of Pentazocine and Thioridazine. Schizophrenia [6A20] [28]
Aripiprazole DM3NUMH Major Additive CNS depression effects by the combination of Pentazocine and Aripiprazole. Schizophrenia [6A20] [28]
Iloperidone DM6AUFY Major Additive CNS depression effects by the combination of Pentazocine and Iloperidone. Schizophrenia [6A20] [28]
Paliperidone DM7NPJS Major Additive CNS depression effects by the combination of Pentazocine and Paliperidone. Schizophrenia [6A20] [28]
Perphenazine DMA4MRX Major Additive CNS depression effects by the combination of Pentazocine and Perphenazine. Schizophrenia [6A20] [28]
Molindone DMAH70G Major Additive CNS depression effects by the combination of Pentazocine and Molindone. Schizophrenia [6A20] [28]
Thiothixene DMDINC4 Major Additive CNS depression effects by the combination of Pentazocine and Thiothixene. Schizophrenia [6A20] [49]
Trifluoperazine DMKBYWI Major Additive CNS depression effects by the combination of Pentazocine and Trifluoperazine. Schizophrenia [6A20] [28]
Risperidone DMN6DXL Major Additive CNS depression effects by the combination of Pentazocine and Risperidone. Schizophrenia [6A20] [28]
Asenapine DMSQZE2 Major Additive CNS depression effects by the combination of Pentazocine and Asenapine. Schizophrenia [6A20] [28]
Pimozide DMW83TP Major Additive CNS depression effects by the combination of Pentazocine and Pimozide. Schizophrenia [6A20] [28]
Fentanyl DM8WAHT Major Additive CNS depression effects by the combination of Pentazocine and Fentanyl. Sensation disturbance [MB40] [25]
Brilinta DMBR01X Moderate Altered absorption of Pentazocine due to GI dynamics variation caused by Brilinta. Thrombosis [DB61-GB90] [41]
Clopidogrel DMOL54H Moderate Altered absorption of Pentazocine due to GI dynamics variation caused by Clopidogrel. Thrombosis [DB61-GB90] [41]
Tizanidine DMR2IQ4 Major Additive CNS depression effects by the combination of Pentazocine and Tizanidine. Tonus and reflex abnormality [MB47] [28]
⏷ Show the Full List of 93 DDI Information of This Drug

References

1 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
2 FDA approval: ado-trastuzumab emtansine for the treatment of patients with HER2-positive metastatic breast cancer. Clin Cancer Res. 2014 Sep 1;20(17):4436-41.
3 BDDCS applied to over 900 drugs
4 Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
5 Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
6 Functional characterization of a sigma receptor and its gene expression by haloperidol. Nippon Yakurigaku Zasshi. 1999 Jul;114(1):61-8.
7 Propiram. A review of its pharmacodynamic and pharmacokinetic properties, and clinical use as an analgesic. Drugs. 1993 Sep;46(3):428-45.
8 Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
9 Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
10 MDR1 (ABCB1) G1199A (Ser400Asn) polymorphism alters transepithelial permeability and sensitivity to anticancer agents. Cancer Chemother Pharmacol. 2009 Jun;64(1):183-8.
11 Folate transporter expression decreases in the human placenta throughout pregnancy and in pre-eclampsia. Pregnancy Hypertens. 2012 Apr;2(2):123-31.
12 Comparative studies on in vitro methods for evaluating in vivo function of MDR1 P-glycoprotein. Pharm Res. 2001 Dec;18(12):1660-8.
13 Antiestrogens and steroid hormones: substrates of the human P-glycoprotein. Biochem Pharmacol. 1994 Jul 19;48(2):287-92.
14 Association of genetic polymorphisms in the influx transporter SLCO1B3 and the efflux transporter ABCB1 with imatinib pharmacokinetics in patients with chronic myeloid leukemia. Ther Drug Monit. 2011 Apr;33(2):244-50.
15 Methadone treatment and its dangers. Medicina (Kaunas). 2009;45(5):419-25.
16 The mu1 and mu2 opioid receptor binding of ketobemidone, norketobemidone and 3-dimethylamino-1,1-diphenylbutene. Pharmacol Toxicol. 1996 Aug;79(2):103-4.
17 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7094).
18 Retrospective diagnosis of an adverse drug reaction in a breastfed neonate: liquid chromatography-tandem mass spectrometry quantification of dextropropoxyphene and norpropoxyphene in newborn and maternal hair. J Anal Toxicol. 2008 Nov-Dec;39(9):787-9.
19 mu-opioid receptor-stimulated synthesis of reactive oxygen species is mediated via phospholipase D2. J Neurochem. 2009 Aug;110(4):1288-96.
20 An evaluation of mu-opioid receptor (OPRM1) as a predictor of naltrexone response in the treatment of alcohol dependence: results from the Combined Pharmacotherapies and Behavioral Interventions for Alcohol Dependence (COMBINE) study. Arch Gen Psychiatry. 2008 Feb;65(2):135-44.
21 Comparison of the effects of dextromethorphan, dextrorphan, and levorphanol on the hypothalamo-pituitary-adrenal axis. J Pharmacol Exp Ther. 2004 May;309(2):515-22.
22 Unconditioned behavioral effects of the powerful kappa-opioid hallucinogen salvinorin A in nonhuman primates: fast onset and entry into cerebrospin... J Pharmacol Exp Ther. 2009 Feb;328(2):588-97.
23 Actions of tilidine and nortilidine on cloned opioid receptors. Eur J Pharmacol. 2005 Jan 4;506(3):205-8.
24 Affinities of dihydrocodeine and its metabolites to opioid receptors. Pharmacol Toxicol. 2002 Aug;91(2):57-63.
25 Product Information. Buprenex (buprenorphine). Reckitt and Colman Pharmaceutical, Richmond, VA.
26 Product Information. Apadaz (acetaminophen-benzhydrocodone). KemPharm, Inc, Coralville, IA.
27 US Food and Drug Administration "FDA warns about serious risks and death when combining opioid pain or cough medicines with benzodiazepines requires its strongest warning.".
28 US Food and Drug Administration "FDA warns about serious risks and death when combining opioid pain or cough medicines with benzodiazepines requires its strongest warning.".
29 Vizcaychipi MP, Walker S, Palazzo M "Serotonin syndrome triggered by tramadol." Br J Anaesth 99 (2007): 919. [PMID: 18006535]
30 Cerner Multum, Inc. "UK Summary of Product Characteristics.".
31 Achamallah NS "Visual hallucinations after combining fluoxetine and dextromethorphan ." Am J Psychiatry 149 (1992): 1406. [PMID: 1530079]
32 Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7. [PMID: 3725002]
33 Gill SS, Wright EM, Reilly CS "Pharmacokinetic interaction of propofol and fentanyl: single bolus injection study." Br J Anaesth 65 (1990): 760-5. [PMID: 2265045]
34 Sturner WQ, Garriott JC "Deaths involving propoxyphene: a study of 41 cases over a two-year period." JAMA 223 (1973): 1125-30. [PMID: 4739371]
35 Cerner Multum, Inc. "Australian Product Information.".
36 Eckhardt K, Ammon S, Hofmann U, Riebe A, Gugeler N, Mikus G "Gabapentin enhances the analgesic effect of morphine in healthy volunteers." Anesth Analg 91 (2000): 185-91. [PMID: 10866910]
37 Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates). Braintree Laboratories, Braintree, MA.
38 Product Information. Zulresso (brexanolone). Sage Therapeutics, Inc., Cambridge, MA.
39 Product Information. Addyi (flibanserin). Sprout Pharmaceuticals, Raleigh, NC.
40 Product Information. Thalomid (thalidomide). Celgene Corporation, Warren, NJ.
41 Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare "Centro de informacion online de medicamentos de la AEMPS - CIMA.".
42 Product Information. Reglan (metoclopramide). Wyeth-Ayerst Laboratories, Philadelphia, PA.
43 Canadian Pharmacists Association.
44 Product Information. Wellbutrin XL (buPROPion). GlaxoSmithKline, Philadelphia, PA.
45 Chan BSH, Graudins A, Whyte IM, Dawson AH, Braitberg G, Duggin GG "Serotonin syndrome resulting from drug interactions." Med J Aust 169 (1998): 523-5. [PMID: 9861909]
46 Product Information. Belviq (lorcaserin). Eisai Inc, Teaneck, NJ.
47 Product Information. Alphagan (brimonidine ophthalmic). Allergan Inc, Irvine, CA.
48 Product Information. Artane (trihexyphenidyl). Lederle Laboratories, Wayne, NJ.
49 Cerner Multum, Inc. "Canadian Product Information.".